AstraZeneca (BUE:AZN) Other Current Liabilities: ARS1,418,992 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:AZN AstraZeneca PLC BUE:AZN
75 GF Score
Price ARS62,175.00
GF Value ARS71,006.31
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Other Current Liabilities?

AstraZeneca BUE:AZN -1.07% 75 Other Current Liabilities is ARS1,418,992 Mil as of Jun. 2026. GuruFocus rates BUE:AZN with a GF Score™ of 75/100 and a GF Value™ of ARS71,006.31 (Modestly Undervalued). The stock has 1 warning sign investors should review.

AstraZeneca's other current liabilities for the quarter that ended in Jun. 2026 was ARS1,418,992 Mil.

AstraZeneca's quarterly other current liabilities declined from Dec. 2025 (ARS29,179,283 Mil) to Mar. 2026 (ARS1,128,384 Mil) but then increased from Mar. 2026 (ARS1,128,384 Mil) to Jun. 2026 (ARS1,418,992 Mil).

AstraZeneca's annual other current liabilities increased from Dec. 2023 (ARS6,401,974 Mil) to Dec. 2024 (ARS17,486,130 Mil) and increased from Dec. 2024 (ARS17,486,130 Mil) to Dec. 2025 (ARS29,179,283 Mil).

AstraZeneca Other Current Liabilities Related Terms

AstraZeneca Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for AstraZeneca's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Other Current Liabilities Chart

AstraZeneca Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,508,386.61 2,514,582.28 6,401,974.01 17,486,130.18 29,179,283.13

AstraZeneca Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,505,411.71 1,636,404.94 29,179,283.13 1,128,383.79 1,418,992.49
BUE:AZN
75GF Score
AstraZeneca PLC BUE:AZN
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ARS1,418,992 Mil mean?
AstraZeneca (BUE:AZN) has a Other Current Liabilities of ARS1,418,992 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on AstraZeneca.
Is AstraZeneca's Other Current Liabilities too high?
AstraZeneca's current Other Current Liabilities is ARS1,418,992 Mil. Overall, AstraZeneca has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's Other Current Liabilities compare to LLY and JNJ?
AstraZeneca's Other Current Liabilities of ARS1,418,992 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on AstraZeneca. AstraZeneca's current Other Current Liabilities is ARS1,418,992 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca (BUE:AZN) is currently considered Modestly Undervalued. The stock's GF Value™ is ARS71,006.31, compared to a current price of ARS62,175.00 — trading 12.4% below its estimated fair value. The current Other Current Liabilities is ARS1,418,992 Mil. AstraZeneca's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For AstraZeneca (BUE:AZN), the current Other Current Liabilities is ARS1,418,992 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca (BUE:AZN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of ARS62,175.00 is trading 12.4% below its estimated GF Value™ of ARS71,006.31. GuruFocus considers AstraZeneca to be Modestly Undervalued.

Key valuation signals for BUE:AZN:

  • Other Current Liabilities: ARS1,418,992 Mil
  • GF Value™: ARS71,006.31 vs. price of ARS62,175.00 (12.4% below fair value)
  • GF Score™: 75/100 with 1 warning sign

No single metric tells the full story. See the BUE:AZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
75GF Score

Get the complete analysis for BUE:AZN

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS62,175.00
Price
ARS71,006.31
GF Value